Novalgin (Metamizole Sodium Monohydrate)

Metamizole sodium provides analgesic and antipyretic effects by non‑selectively inhibiting cyclooxygenase enzymes, which lowers prostaglandin production. The reduction in prostaglandins diminishes peripheral pain signalling, while central mechanisms and smooth‑muscle spasmolysis contribute to its overall therapeutic action.

The dose of Novalgin is determined by the prescribing clinician based on the patient’s condition, severity of pain or fever, and individual health factors. Dosage adjustments may be required for renal or hepatic impairment, and the medication should be administered only under medical supervision.

Safety data for metamizole sodium in pregnancy and lactation are limited, and the drug is generally not recommended unless the potential benefit outweighs the risk. Healthcare providers should evaluate each case individually and consider alternative therapies when possible.

To order Novalgin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Novalgin belongs to the pyrazolone class and offers rapid, potent analgesia and antipyresis, often stronger than paracetamol and comparable to strong NSAIDs. Unlike many NSAIDs, it has a distinct risk profile, notably the potential for agranulocytosis, which requires careful monitoring.

Novalgin should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from light, moisture and extreme temperatures. Before administration, inspect the vial for particulate matter and ensure the solution is clear.

Novalgin is supplied as an injectable solution and can be given either intramuscularly or intravenously. Administration is performed by qualified healthcare personnel, following aseptic technique and appropriate dosing guidelines set by the prescriber.

The most critical safety concerns include agranulocytosis, severe skin reactions such as Stevens‑Johnson syndrome, anaphylaxis, and hemolytic anemia. Patients should be monitored for signs of infection, rash, breathing difficulty or sudden drop in blood pressure, and the drug should be discontinued immediately if these occur.

Novalgin is contraindicated in individuals with known hypersensitivity to metamizole or other pyrazolones, a history of agranulocytosis, severe liver or kidney disease, and in patients where the risk of severe adverse reactions outweighs the therapeutic benefit.